c-LEcta increases market presence in the USA
c-LEcta establishes a US warehouse for R&D-grade DENARASE® portfolio and partners with local distributor
With the signing of a contract with the US life science distributor Biohippo Inc., c-LEcta improves the availability of its DENARASE products in the USA. c-LEcta can now directly supply R&D-grade DENARASE products from a local US ware-house in Gaithersburg, Maryland. The warehouse is operated by Biohippo.
US Customers will benefit from a stronger and more sustainable supply chain, with significantly reduced delivery times and no need for customs clearance. All DENARASE R&D-grades and the DENARASE ELISA kit will be stored and delivered from the local US warehouse, thereby ensuring seamless and flexible access for customers’ R&D projects. GMP-grade DENARASE will continue to be delivered directly from c-LEcta’s GMP warehouse located in Leipzig, Germany, in order to ensure adherence to strict regulatory and quality standards. In addition to partnering on the warehouse, Biohippo will also act as a distributor for all DENARASE® products, further simplifying the ordering process for local US customers.
This partnership is part of a strategic focus of c-LEcta on the US biopharma market. Already at the beginning of the year, a joint marketing partnership for DENARASE was agreed with the Kerry Group, including additional local US market presence. c-LEcta has been part of the Irish Kerry Group since 2022. Since April of this year the DENARASE Sales team has also been strengthened with a regional US manager providing local technical and application support.
DENARASE is an endonuclease enzyme used to degrade unwanted DNA and RNA during the manufacturing of biopharmaceutical products, for example viral vectors for cell and gene therapies. For years, c-LEcta has been very successful with its DENARASE products in the USA, representing over 40% of global sales. Hundreds of biopharma customers from pre-/clinical up to commercial manufacturing rely on the quality of DENARASE, including some of the most renowned US biopharmaceutical companies.
c-LEcta is a global biotechnology company specializing in the development, production and distribution of enzyme products. The company uses world-class enzyme engineering and production technologies to provide its partners in the food and pharmaceutical industries with superior biotechnological solutions for innovative industrial applications. Product develop-ment is based on the proprietary enzyme technology platform ENESYZ® and is carried out both in-house and in close cooperation with industry partners worldwide. c-LEcta supplies its products to more than 400 customers in over 40 countries. c-LEcta currently employs about 130 people at its headquarters in Leipzig.
c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.
Biohippo stands at the forefront of life science research facilitation. Biohippo Inc. is headquartered in Gaithersburg, Maryland. Their objective is clear: to provide researchers with an efficient conduit to essential research tools and resources. Through their comprehensive online platform, Biohippo offers an extensive selection of life science research products and services from multiple suppliers. Biophippo have also garnered significant recognition for their prowess in sourcing rare and specialized items.